Abstract

Background: Tuberculosis, mainly caused by Mycobacterium tuberculosis (Mtb), is an ancient human disease that gravely affects millions of people annually. We wanted to explore the genetic diversity and lineage-specific association of Mtb with drug resistance among pulmonary tuberculosis patients.Methods: Sputum samples were collected from pulmonary tuberculosis patients at six different healthcare institutions in Tigray, Ethiopia, between July 2018 and August 2019. DNA was extracted from 74 Mtb complex isolates for whole-genome sequencing (WGS). All genomes were typed and screened for mutations with known associations with antimicrobial resistance using in silico methods, and results were cross-verified with wet lab methods.Results: Lineage (L) 4 (55.8%) was predominant, followed by L3 (41.2%); L1 (1.5%) and L2 (1.5%) occurred rarely. The most frequently detected sublineage was CAS (38.2%), followed by Ural (29.4%), and Haarlem (11.8%). The recent transmission index (RTI) was relatively low. L4 and Ural strains were more resistant than the other strains to any anti-TB drug (P < 0.05). The most frequent mutations to RIF, INH, EMB, SM, PZA, ETH, FLQs, and 2nd-line injectable drugs occurred at rpoB S450L, katG S315T, embB M306I/V, rpsL K43R, pncA V139A, ethA M1R, gyrA D94G, and rrs A1401G, respectively. Disputed rpoB mutations were also shown in four (16%) of RIF-resistant isolates.Conclusion: Our WGS analysis revealed the presence of diverse Mtb genotypes. The presence of a significant proportion of disputed rpoB mutations highlighted the need to establish a WGS facility at the regional level to monitor drug-resistant mutations. This will help control the transmission of DR-TB and ultimately contribute to the attainment of 100% DST coverage for TB patients as per the End TB strategy.

Highlights

  • Tuberculosis (TB), caused by closely related Mycobacterium tuberculosis (Mtb) complex (MTBC) species, is an ancient human disease that continues to affect millions of people every year worldwide

  • The current study provides insight into Mtb strains circulating in the region, the mutation that confers drug resistance (DR) to the anti-TB drugs and the association of frequently observed lineages and circulating sublineages with anti-TB drugs

  • These findings can be used to scale up the present laboratory techniques in a way that can offer rapid and accurate results for the regular DR surveillance to interrupt the ongoing drug resistant tuberculosis (DR-TB) transmission, proper management of multidrug-resistant tuberculosis (MDR-TB) as well as to design tailored TB control strategies in the region

Read more

Summary

Introduction

Tuberculosis (TB), caused by closely related Mtb complex (MTBC) species, is an ancient human disease that continues to affect millions of people every year worldwide. Ethiopia is among the top 30 of high TB-burden countries globally, with 157,000 incident TB cases in 2019 (World Health Organization, 2019). The seven MTBC lineages are associated with the different epidemiological profiles, host range, pathogenicity, geographic regions, and drug resistance (DR) (Coscolla and Gagneux, 2014). Discovered lineages of MTBC are claimed to be restricted to the African Great Lakes region (L8) (Ngabonziza et al, 2020) and East Africa (L9) (Coscolla et al, 2021). We wanted to explore the genetic diversity and lineage-specific association of Mtb with drug resistance among pulmonary tuberculosis patients

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call